Pasig,
Philippines, November
2018 – Mylan, one of the world’s leading global pharmaceutical companies, in
association with the Hepatology Society of Philippines (HSP), launched an
awareness campaign for Hepatitis C in the country. The BEATHepC (Become
educated, aware, tested and treated) campaign aims at spreading awareness about
the disease. It will include dissemination of information through pamphlets and
promoting screening among Filipinos at risk.
The Department of Health (DoH) estimates
that around 1% of the Filipino population has chronic hepatitis C1. According to the 2010 study on Global Burden
of Disease by the Institute for Health Metrics and Evaluation, university of
Washington viral hepatitis causes 1 million deaths each year in the Asia
Pacific region. Hepatitis C is endemic in the Philippines and there is a lack
of awareness about viral hepatitis and its transmission, prevention, screening,
and management among patients, public, and healthcare providers.
Speaking at the launch event, Dr. Jade
Jamias, Liver Specialist and President of HSP said, “Chronic Hepatitis C
infection may lead to serious complications such as cirrhosis and/or liver cancer.
Patients with hepatitis C often do not show early symptoms and so it becomes
very critical to educate the people about this infection. Early detection is
key to treatment and prevention of liver disease progression. The positive news
is that treatment for this disease is now easily accessible to all.”
Ms. Ester Tacanay, Country Manager of
Mylan in Philippines said, “Hepatitis C is a chronic public health concern in
the Philippines. At Mylan Philippines we are committed to provide access to
medicine for treatment of hepatitis C with the objective of reducing the disease
burden. Through the BEATHepC campaign Mylan aims to create awareness around
risks and misconceptions about the disease and encourage early screening and
treatment to prevent the disease. We are happy to partner with HSP to drive
this campaign across Philippines.”
Mylan’s
BEATHepC campaign supports the National Viral Hepatitis Task Force (NVHTF) 2 to eliminate or significantly decrease the
prevalence of hepatitis B and hepatitis C in the Philippines.
About Hepatitis C
Hepatitis C is a disease that affects the liver and is caused by the hep C virus. Hep C is usually spread when blood from a person infected with the hep C virus enters the body of someone who is not infected. Hep C generally progresses slowly, over the course of 10 to 40 years. It attacks and damages the liver, killing liver cells in the process. As a result, scar tissue forms, a process called fibrosis. For about 10 to 20 percent of people infected, Hep C can eventually lead to scarring of the liver (also called cirrhosis). Although some people will experience symptoms, about 80 percent of people with acute Hep C do not have any symptoms.
Hepatitis C is a disease that affects the liver and is caused by the hep C virus. Hep C is usually spread when blood from a person infected with the hep C virus enters the body of someone who is not infected. Hep C generally progresses slowly, over the course of 10 to 40 years. It attacks and damages the liver, killing liver cells in the process. As a result, scar tissue forms, a process called fibrosis. For about 10 to 20 percent of people infected, Hep C can eventually lead to scarring of the liver (also called cirrhosis). Although some people will experience symptoms, about 80 percent of people with acute Hep C do not have any symptoms.
About
Mylan
Mylan is a global pharmaceutical
company committed to setting new standards in healthcare. Working together
around the world to provide 7 billion people access to high quality medicine,
we innovate to satisfy unmet needs; make reliability and service excellence a
habit; do what's right, not what's easy; and impact the future through
passionate global leadership. We offer a growing portfolio of more than 7,500
marketed products around the world, including antiretroviral therapies on which
more than 40% of people being treated for HIV/AIDS globally depend. We market
our products in more than 165 countries and territories. We are one of the
world's largest producers of active pharmaceutical ingredients. Every member of
our approximately 35,000-strong workforce is dedicated to creating better
health for a better world, one person at a time. Learn more at Mylan.com. We routinely post
information that may be important to investors on our website at investor.mylan.com.
About
Hepatology Society of the Philippines
The Hepatology Society of the
Philippines is a non-governmental organization committed to:
·
Provide and promote comprehensive information
to the public and to the medical community.
·
Promote research to advance the field of
hepatology to provide relevant care to patients.
·
Collaborate with the government in
formulating in liver related health policies
·
Share information, services and expertise
with the global community towards the prevention and treatment of liver
diseases
It is the only liver society
recognized by the Philippine Medical Association, Philippine College of
Physicians, Philippine Society of Gastroenterology and Philippine Society of
Digestive Endoscopy. For further information, visit www.hsp.org.ph
No comments:
Post a Comment